Lubiprostone

Outlook on the Chronic Idiopathic Constipation Drugs Global Market to 2030 - Featuring Actavis, Pfizer and Sanofi Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022
Health, Pharmaceutical, CIC, Plecanatide, Linaclotide, Rest, OTC, Patient, Pharmaceutical industry, Lubiprostone

The global chronic idiopathic constipation (CIC) drugs market is moderately competitive and is characterized by a large demand for over the counter medications.

Key Points: 
  • The global chronic idiopathic constipation (CIC) drugs market is moderately competitive and is characterized by a large demand for over the counter medications.
  • This report on CIC drugs market studies, estimates and forecasts the market for various drugs indicated for the treatment of chronic idiopathic constipation.
  • The prescription-based market for CIC drugs is classified as prescribed CIC drugs market and OTC CIC drugs markets.
  • The report concludes with mapping of the key CIC drugs manufacturers operating in the global CIC drugs market.

Global Irritable Bowel Syndrome (IBS) Market Outlook Report 2022: Opportunity and Demand Analysis & Market Forecasts, 2019-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 1, 2022
Health, Pharmaceutical, Anxiety and Depression Association of America, Eluxadoline, Population, Abdominal pain, Growth, Allergan, Inc., Prevalence, Awareness, International Foundation, Diarrhea, IBS, Bloating, Alosetron, Rifaximin, Irritable bowel syndrome, Medicine, Disease, Functional gastrointestinal disorder, Lubiprostone, Anxiety, IBS-C, IBS-D, Adoption, USD, Allergan, Constipation, Female, Patient, Cramp, Depression, CAGR, German East Africa Company, Association, Incidence, AstraZeneca, Pharmaceutical industry, Fine chemical, Ironwood, Linaclotide

The "Global Irritable Bowel Syndrome Market Outlook: Opportunity And Demand Analysis, Market Forecast, 2019-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Irritable Bowel Syndrome Market Outlook: Opportunity And Demand Analysis, Market Forecast, 2019-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global irritable bowel syndrome treatment market size was valued at USD 1.5 billion in 2019 and is anticipated to exhibit a CAGR of 10.1% over the forecast period.
  • The disease is additionally referred to as irritable bowel syndrome, irritable bowel syndrome, spastic colitis, and irritable colon.
  • According to International Foundation for Functional Gastrointestinal Disorders, 2019, the worldwide prevalence of irritable bowel syndrome is around 10-15%.

Outlook on the Irritable Bowel Syndrome Treatment Global Market to 2028 - by Type, Product, Distribution Channel and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Health, General Health, Medical specialties, Clinical medicine, Gastroenterology, Abdominal pain, Irritable bowel syndrome, Lactams, Imidazoles, Lubiprostone, Rifaximin, Eluxadoline, Immuron, Small intestinal bacterial overgrowth

The factors such as increasing prevalence of irritable bowel syndrome (IBS) diseases and rising research & development activities drive the market growth.

Key Points: 
  • The factors such as increasing prevalence of irritable bowel syndrome (IBS) diseases and rising research & development activities drive the market growth.
  • However, the limited number of product availability and treatment inefficiency hinder the growth of the irritable bowel syndrome (IBS) treatment market.
  • The global irritable bowel syndrome (IBS) treatment market is segmented on the basis of type, product, and distribution channel.
  • The irritable bowel syndrome (IBS) treatment market, based on product, is segmented into rifaximin, eluxadoline, lubiprostone, linaclotide, and others.

Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation

Retrieved on: 
Tuesday, March 2, 2021
Digestive diseases, Clinical medicine, Medical specialties, Waterborne diseases, Feces, Abdominal pain, Irritable bowel syndrome, Diarrhea, Constipation, Knight Therapeutics, Lubiprostone, Alosetron

MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (Knight) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Key Points: 
  • MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (Knight) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
  • In the clinical development of IBSRELA diarrhea was the most common adverse event reported by patients often occurring during the first week of treatment.
  • Even with the current therapeutic options, many patients suffering from constipation predominant irritable bowel syndrome remain dissatisfied with the current treatments available.
  • Dr. Louis Liu has received honoraria from Knight Therapeutics Inc. as a consulting physician relating to medical advisory board participation.

Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting

Retrieved on: 
Thursday, October 22, 2020
Digestive diseases, Medical specialties, Gastroenterology, RTT, Functional constipation, Plecanatide, Constipation, Irritable bowel syndrome, Abdominal pain, Gastrointestinal tract, Lubiprostone

"Salix continues to demonstrate its longstanding commitment to the GI community by presenting this broad collection of clinical data that span our portfolio at ACG.

Key Points: 
  • "Salix continues to demonstrate its longstanding commitment to the GI community by presenting this broad collection of clinical data that span our portfolio at ACG.
  • The complete list of scientific posters that will be presented by Salix during ACG includes:
    Bharucha, Adil.
  • "The Impact of Plecanatide on Abdominal Pain in Patients with Chronic Idiopathic Constipation and Irritable Bowel Syndrome with Constipation: Analysis from Four Phase 3 Studies."
  • "Efficacy and Safety of Plecanatide in Patients with Chronic Idiopathic Constipation or Irritable Bowel Syndrome with Constipation: Intrinsic Factors Analyses from Four Studies."

SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome

Retrieved on: 
Thursday, May 14, 2020
Medicine, Digestive diseases, Medical specialties, RTT, Waterborne diseases, Feces, Abdominal pain, Irritable bowel syndrome, Diarrhea, Constipation, Alosetron, Lubiprostone

CHENGDU, China, May 13, 2020 /PRNewswire/ -- SciMount Pharmatech, Co. Ltd., a wholly-owned subsidiary of Xiling Lab, announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for SMP-100 for the treatment of Irritable Bowel Syndrome with diarrhea (IBS-D).

Key Points: 
  • CHENGDU, China, May 13, 2020 /PRNewswire/ -- SciMount Pharmatech, Co. Ltd., a wholly-owned subsidiary of Xiling Lab, announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for SMP-100 for the treatment of Irritable Bowel Syndrome with diarrhea (IBS-D).
  • "This IND approval is an important step in SciMount's ambition to be a global leader in innovative therapeutics for the treatment of gastrointestinal diseases," said Dejian Xie, PhD, General Manager at SciMount.
  • IBS is a chronic and sometimes disabling bowel disorder that is often associated with severe abdominal pain.
  • There currently is no adequate treatment for IBS-D and no approved therapeutic for the treatment of IBS with alternating symptoms between diarrhea and constipation (IBS-mixed or IBS-M).

Sebela Pharmaceuticals Announces FDA Approval of Pizensy™ for oral solution for the Treatment of Chronic Idiopathic Constipation in Adults

Retrieved on: 
Monday, March 2, 2020
Digestive diseases, Medical specialties, Gastroenterology, RTT, Constipation, Laxatives, Functional constipation, Irritable bowel syndrome, Lactitol, Lubiprostone, Linaclotide

BRAINTREE, Mass., March 2, 2020 /PRNewswire-PRWeb/ -- Sebela Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Pizensy (lactitol) for oral solution for the once-daily treatment of chronic idiopathic constipation (CIC) in adults.

Key Points: 
  • BRAINTREE, Mass., March 2, 2020 /PRNewswire-PRWeb/ -- Sebela Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Pizensy (lactitol) for oral solution for the once-daily treatment of chronic idiopathic constipation (CIC) in adults.
  • "The approval of Pizensy represents a major step forward in treatment options for CIC.
  • 1Thomas R, Luthin D. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
  • Prevalence of, and risk factors for chronic idiopathic constipation in the community: systematic review and meta-analysis.

IFFGD Recognizes December as Constipation Awareness Month with the Launch of Animated Patient's Guide to Constipation

Retrieved on: 
Thursday, December 5, 2019
Digestive diseases, Medical specialties, Gastroenterology, RTT, Constipation, Laxatives, Lubiprostone

MOUNT PLEASANT, S.C., Dec. 5, 2019 /PRNewswire/ --December is Constipation Awareness Month.

Key Points: 
  • MOUNT PLEASANT, S.C., Dec. 5, 2019 /PRNewswire/ --December is Constipation Awareness Month.
  • What is constipation?
  • Who is impacted by constipation?
  • Chronic constipation affects up to 20% of adults and 16% of children in the United States.

Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

Retrieved on: 
Thursday, September 12, 2019
Medicine, Medical specialties, Digestive diseases, RTT, Gastroenterology, Irritable bowel syndrome, Laxatives, Constipation, Abdominal pain, Lubiprostone, Alosetron

Patients who were enrolled in these trials met the Rome III criteria for IBS-C, related to abdominal pain and bowel movement frequency.

Key Points: 
  • Patients who were enrolled in these trials met the Rome III criteria for IBS-C, related to abdominal pain and bowel movement frequency.
  • The primary endpoint for both trials was the proportion of patients who were responders during the 12-week treatment period.
  • IBSRELA (tenapanor) is indicated for treatment of irritable bowel syndrome with constipation(IBS-C) in adults.
  • On September 12, 2019, Ardelyx received approval of IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C).

FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65

Retrieved on: 
Monday, April 1, 2019
Chemical compounds, Medicine, Digestive diseases, RTT, Abdominal pain, Irritable bowel syndrome, Tegaserod, Constipation, Serotonin, Alosetron, Lubiprostone

A positive GIDAC vote and FDA review both supported the reintroduction of Zelnorm for appropriate IBS-C patients.

Key Points: 
  • A positive GIDAC vote and FDA review both supported the reintroduction of Zelnorm for appropriate IBS-C patients.
  • "We are excited about what the reintroduction of Zelnorm means for patients suffering from irritable bowel syndrome with constipation.
  • ZELNORM is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).
  • A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.